Printer Friendly

Ulrich M. Grau Joins Enzon as Chief Scientific Officer.

Business Editors & Health/Medical Writers

PISCATAWAY, NJ.--(BUSINESS WIRE)--March 18, 2002

Enzon, Inc. (NASDAQ:ENZN) announced today the appointment of Ulrich M. Grau, Ph.D. as the Company's Chief Scientific Officer.

In this role, Dr. Grau will be responsible for advancing the Company's product pipeline; expanding its research and development programs and technology base; and advising the board and management on the scientific vision and direction of the Company.

Dr. Grau brings over 20 years of experience from the biotechnology and pharmaceutical industry having directed numerous R&D programs. Most notably, Dr. Grau served as President of Research and Development at BASF Pharma and Senior VP Global Product Realization for Hoechst Marion Roussel. While at BASF, Dr. Grau directed a global R&D organization of approximately 1,500 employees, and significantly advanced and expanded the Company's product portfolio. At Hoechst, Dr. Grau served as Senior VP Global Product Realization, where he directed the company's late-stage product development activities.

"A key pillar of Enzon's strategy to become a fully integrated pharmaceutical company is a commitment to excellence in research and development," said Arthur J. Higgins, Enzon's chairman and chief executive officer. "Ulrich is a respected and accomplished leader in pharmaceutical development whose past work experience at both BASF and Hoechst showcases an impressive track record of bringing products from research through the clinic to the marketplace."

"I look forward to advancing the company's research program by building upon past successes, as well as expanding Enzon's pharmaceutical pipeline," said Dr. Grau. "Enzon's leading technologies, and management's commitment to broadening Enzon's research and clinical programs, were deciding factors in my accepting this position. With these elements in place, I am confident I will be able to successfully contribute to Enzon's vision."

Jeffrey McGuire, Ph.D. has been named the Company's Senior Vice President of Scientific Affairs. In this capacity, Dr. McGuire will be reporting to Dr. Grau and will be focused on identifying and gaining access to new preclinical candidates and drug delivery technologies to expand the Company's proprietary pipeline.

Enzon is a biopharmaceutical company that develops and commercializes enhanced therapeutics for life-threatening diseases through the application of its proprietary platform technologies: PEG Modification and single-chain antibodies (SCA(R)). Three products that utilize Enzon's technology are currently marketed: PEG-INTRON marketed by Schering-Plough for hepatitis C, ONCASPAR(R) for Acute Lymphoblastic Leukemia (ALL), and ADAGEN(R) a treatment for a form of Severe Combined Immunodeficiency Disease (SCID), commonly known as the "Bubble Boy Disease." In addition to three approved products, Enzon has several products in various stages of clinical development by itself and with partners, including additional indications for PEG-INTRON with Schering-Plough. A Phase III clinical trial is being conducted for PEG-INTRON for the treatment of malignant melanoma. Enzon develops and markets products on its own and through strategic alliances, which in addition to Schering-Plough Corporation include Alexion Pharmaceuticals, Inc., Baxter Healthcare Corporation, Bristol-Myers Squibb Company, Eli Lilly & Company, and Aventis.

Except for the historical information herein, the matters discussed in this news release include forward-looking statements that may involve a number of risks and uncertainties. Actual results may vary significantly based upon a number of factors, which are described in the Company's Form 10-K, Form 10-Q's and Form 8-K's on file with the SEC, including without limitation, risks in obtaining and maintaining regulatory approval for indications and expanded indications, market acceptance of and continuing demand for Enzon's products and the impact of competitive products and pricing.

This release is also available at http://www.enzon.com
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Mar 18, 2002
Words:584
Previous Article:America Online With AOL Moviefone Announce the Winners of The Seventh Annual American Moviegoer Awards Presented by Royal Philips Electronics.
Next Article:Wallstreet-Review's Financial Subsidiary Closes First Deal!
Topics:


Related Articles
RBX appoints Roland president/CEO.
The board of directors of Columbian Chemicals named John T. Walsh president.
Witco's board of directors confirmed the appointment of Camillo J. DiFrancesco as chief financial officer.
Taras Konowal as named president of Bucher.
Jeffrey B. Miller was appointed president of Spectra, a Markem subsidiary.
NECA Celebrates 100th Anniversary With Community Service.
Enzon And Micromet To Host Technology Briefing On Single-Chain Antibody Collaboration.
ENZON/INEX SIGN COMMERCIALIZATION PACT FOR ONCOLOGY DRUG ONCO TCS.
Heitmann chosen to lead Lanxess.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters